Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07650357 · ClinicalTrials.gov registry record · Phase 1
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
A Phase 1 study, sponsored by Clasp Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT07650357 is a Phase 1 study that has not yet begun recruiting, run by Clasp Therapeutics. The registered enrollment target is 140 participants.
The verdict
NCT07650357, a Phase 1 study, has not yet begun recruiting, sponsored by Clasp Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
Interventions
- DRUG CLSP-5282
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07650357
The ClinicalTrials.gov registry entry for NCT07650357 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clasp Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CLSP-5282 is the first listed.
NCT07650357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07650357 about?
NCT07650357 is a clinical study titled "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)". Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.
What is the current status of trial NCT07650357?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2026-07. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07650357?
The interventions under investigation include: CLSP-5282 (DRUG).
Who is sponsoring clinical trial NCT07650357?
This trial is sponsored by Clasp Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.